AFP, AFP-L3% and DCP levels in patients with advanced hepatocellular carcinoma treated with sorafenib
H Schulze-Bergkamen, A Weinmann, M Wörns, PR Spies, A Teufel, C Düber, G Otto, A Shresta, B Vick, R Küper, J Schurek, PR Galle, M Schuchmann, M Volkmann · Zeitschrift für Gastroenterologie · 2009 · Heft 01
Bibliografische Angaben
Zusammenfassung
Background: Patients suffering from advanced hepatocellular carcinoma (HCC) have a dismal prognosis with survival rates of less than six months. The multikinase inhibitor sorafenib (Nexavar®) was recently approved for the treatment of advanced HCC providing survival benefit (Llovet, NEJM, 2008). Considering the shortcomings of RECIST criteria in the age of targeted therapy we have investigated serum levels of alpha-Fetoprotein (AFP), AFP-L3% (fraction of AFP binding to Lens culinaris agglutinin) and des-gamma-carboxy-prothrombin (DCP, PIVKA-II) as potential markers for response to sorafenib treatment. Methods: 4…
